Devia introduces an AI agent for pharmaceutical quality investigations
Zurich-based Devia emerged from stealth with an agentic platform for GxP deviations.
AT A GLANCE
Key points
- Devia emerged from stealth after a year of pilots.
- The agent supports intake, root-cause work and CAPA drafting.
- Qualified reviewers remain responsible for decisions.
What is changing?
Zurich-based Devia, a Visium spin-out, introduced an agentic platform for investigating GxP quality deviations in pharmaceutical manufacturing. The system structures the initial report, gathers evidence, proposes root causes and drafts corrective and preventive actions. A qualified professional reviews each step and signs the decision.
Devia says it piloted the platform with quality teams in live GxP environments for a year and cut investigation time in half. Designed for validated systems such as TrackWise, Veeva Vault QMS and MasterControl, the product preserves a trace of AI suggestions and human decisions.
Explore the original sources
Source date: 11 November 2026.
Published by AI Radar: 11 Nov 2026, 12:08 (Istanbul, UTC+3).
FOLLOW THE TOPIC
Topics and tags
Share your discovery.
Send this story to a friend.
Reader comments
What do you think about this development? Share your experience or question. Comments are published after editorial approval.
Your name/nickname and comment become public if approved. Read: Privacy notice.
Loading comments…